Mild cognitive impairment with the core clinical features of dementia with Lewy bodies is recognized as a prodromal stage of dementia with Lewy bodies. Although grey matter atrophy has been demonstrated in prodromal dementia with Lewy bodies, longitudinal rates of atrophy during progression to probable dementia with Lewy bodies are unknown. We investigated the regional patterns of cross-sectional and longitudinal rates of grey matter atrophy in prodromal dementia with Lewy bodies, including those who progressed to probable dementia with Lewy bodies. Patients with mild cognitive impairment with at least one core clinical feature of dementia with Lewy bodies (mean age = 70.5; 95% male), who were enrolled in the Mayo Clinic Alzheimer's Disease Research Center and followed for at least two clinical evaluations and MRI examinations, were included (n = 56). A cognitively unimpaired control group (n = 112) was matched 2:1 to the patients with mild cognitive impairment by age and sex. Patients either remained stable (n = 28) or progressed to probable dementia with Lewy bodies (n = 28) during a similar follow-up period and pathologic confirmation was available in a subset of cases (n = 18). Cross-sectional and longitudinal rates of grey matter atrophy were assessed using voxel-based and atlas-based region of interest analyses. At baseline, prodromal dementia with Lewy bodies was characterized by atrophy in the nucleus basalis of Meynert both in those who remained stable and those who progressed to probable dementia with Lewy bodies (P < 0.05 false discovery rate corrected). Increase in longitudinal grey matter atrophy rates were widespread, with greatest rates of atrophy observed in the enthorhinal and parahippocampal cortices, temporoparietal association cortices, thalamus and the basal ganglia, in mild cognitive impairment patients who progressed to probable dementia with Lewy bodies at follow-up (P < 0.05 false discovery rate corrected). Rates of inferior temporal atrophy were associated with greater rates of worsening on the clinical dementia rating-sum of boxes. Seventeen of the 18 (94%) autopsied cases had Lewy body disease. Results show that atrophy in the nucleus basalis of Meynert is a feature of prodromal dementia with Lewy bodies regardless of proximity to progression to probable dementia with Lewy bodies. Longitudinally, grey matter atrophy progresses in regions with significant cholinergic innervation, in alignment with clinical disease progression, with widespread and accelerated rates of atrophy in patients who progress to probable dementia with Lewy bodies. Given the prominent neurodegeneration in the cholinergic system, patients with prodromal dementia with Lewy bodies may be candidates for cholinesterase inhibitor treatment.

Department of Health Sciences Research Mayo Clinic Rochester MN USA

Department of Laboratory Medicine and Pathology Mayo Clinic Jacksonville FL USA

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

Department of Neurology Charles University Prague Czech Republic

Department of Neurology Mayo Clinic Jacksonville FL USA

Department of Neurology Mayo Clinic Rochester MN USA

Department of Neurology West China Hospital of Sichuan University Chengdu Sichuan China

Department of Psychology and Psychiatry Mayo Clinic Jacksonville FL USA

Department of Psychology and Psychiatry Mayo Clinic Rochester MN USA

Department of Radiology Mayo Clinic Rochester MN USA

Zobrazit více v PubMed

McKeith IG, Ferman TJ, Thomas AJ, et al. . Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743–755. PubMed PMC

Ferman TJ, Smith GE, Kantarci K, et al. . Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013;81:2032–2038. PubMed PMC

Kantarci K, Lesnick T, Ferman TJ, et al. . Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology. 2016;87:2317–2323. PubMed PMC

Durcan R, Donaghy P, Osborne C, Taylor JP, Thomas AJ. Imaging in prodromal dementia with Lewy bodies: Where do we stand? Int J Geriatr Psychiatry. 2019;34:635–646. PubMed

Blanc F, Colloby SJ, Philippi N, et al. . Cortical thickness in dementia with Lewy bodies and Alzheimer’s disease: A comparison of prodromal and dementia stages. PLoS One. 2015;10:e0127396. PubMed PMC

Blanc F, Colloby SJ, Cretin B, et al. . Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther. 2016;8:31. PubMed PMC

Roquet D, Noblet V, Anthony P, et al. . Insular atrophy at the prodromal stage of dementia with Lewy bodies: A VBM DARTEL study. Sci Rep. 2017;7:9437. PubMed PMC

Schumacher J, Taylor JP, Hamilton CA, et al. . In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies. Neuroimage Clin. 2021;30:102604. PubMed PMC

Mak E, Su L, Williams GB, et al. . Progressive cortical thinning and subcortical atrophy in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging. 2015;36:1743–1750. PubMed

Mak E, Su L, Williams GB, et al. . Longitudinal assessment of global and regional atrophy rates in Alzheimer’s disease and dementia with Lewy bodies. Neuroimage Clin. 2015;7:456–462. PubMed PMC

Whitwell JL, Jack CR Jr, Parisi JE, et al. . Rates of cerebral atrophy differ in different degenerative pathologies. Brain. 2007;130(Pt 4):1148–1158. PubMed PMC

Nedelska Z, Ferman TJ, Boeve BF, et al. . Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging. 2015;36:452–461. PubMed PMC

Sarro L, Senjem ML, Lundt ES, et al. . Amyloid-beta deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain. 2016;139(Pt 10):2740–2750. PubMed PMC

Roberts RO, Geda YE, Knopman DS, et al. . The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58–69. PubMed PMC

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999;56:303–308. PubMed

Petersen RC, Roberts RO, Knopman DS, et al. . Mild cognitive impairment: Ten years later. Arch Neurol. 2009;66:1447–1455. PubMed PMC

McKeith IG, Boeve BF, Dickson DW, et al. . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100. PubMed PMC

McKeith IG, Dickson DW, Lowe J, et al. . Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology. 2005;65:1863–1872. PubMed

Kantarci K, Ferman TJ, Boeve BF, et al. . Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology. 2012;79:553–560. PubMed PMC

Ferman TJ, Smith GE, Boeve BF, et al. . DLB fluctuations: Specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62:181–187. PubMed

AAoS . International classification of sleep disorders. Diagnostic and coding manual. American Academy of Sleep Medicine. 2005:51–55.

Fahn S. Recent developments in Parkinson’s disease. Vol. 2. Macmillan Health Care Information; 1987:293–304.

Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839–851. PubMed

Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12:26–41. PubMed PMC

Schwarz CG, Gunter JL, Wiste HJ, et al. . A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer’s disease severity. Neuroimage Clin. 2016;11:802–812. PubMed PMC

Das SR, Avants BB, Grossman M, Gee JC. Registration based cortical thickness measurement. Neuroimage. 2009;45:867–879. PubMed PMC

Cash DM, Frost C, Iheme LO, et al. . Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. Neuroimage. 2015;123:149–164. PubMed PMC

Vemuri P, Senjem ML, Gunter JL, et al. . Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer’s disease. Neuroimage. 2015;113:61–69. PubMed PMC

Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–486. PubMed

Beach TG, White CL, Hamilton RL, et al. . Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008;116:277–288. PubMed PMC

Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1–13. PubMed PMC

Montine TJ, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol. 2012;123:1–11. PubMed PMC

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–134. PubMed

Schmeichel AM, Buchhalter LC, Low PA, et al. . Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology. 2008;70:368–373. PubMed

Hanyu H, Tanaka Y, Sakurai H, Takasaki M, Abe K. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer’s disease. Neurosci Lett. 2002;319:33–36. PubMed

Teipel SJ, Fritz HC, Grothe MJ, Alzheimer’s Disease Neuroimaging Initiative . Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology. 2020;95:e1301–e1311. PubMed PMC

Tiraboschi P, Hansen LA, Alford M, et al. . Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002;59:946–951. PubMed

Hanyu H, Shimizu S, Tanaka Y, Hirao K, Iwamoto T, Abe K. MR features of the substantia innominata and therapeutic implications in dementias. Neurobiol Aging. 2007;28:548–554. PubMed

Galasko D, Hansen LA, Katzman R, et al. . Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol. 1994;51:888–895. PubMed

Gomez-Isla T, Growdon WB, McNamara M, et al. . Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology. 1999;53:2003–2009. PubMed

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–2204. PubMed

Ferreira D, Przybelski SA, Lesnick TG, et al. . beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology. 2020;95:e3257–e3268. PubMed PMC

Chen Q, Lowe VJ, Boeve BF, et al. . β-Amyloid PET and 123I-FP-CIT SPECT in mild cognitive impairment at risk for lewy body dementia. Neurology. 2021;96:e1180–e1189. PubMed PMC

Nedelska Z, Schwarz CG, Lesnick TG, et al. . Association of longitudinal beta-amyloid accumulation determined by positron emission tomography with clinical and cognitive decline in adults with probable lewy body dementia. JAMA Netw Open. 2019;2:e1916439. PubMed PMC

Spotorno N, Coughlin DG, Olm CA, et al. . Tau pathology associates with in vivo cortical thinning in Lewy body disorders. Ann Clin Transl Neurol. 2020;7:2342–2355. PubMed PMC

Siddiqui TG, Whitfield T, Praharaju SJ, et al. . Magnetic resonance imaging in stable mild cognitive impairment, prodromal Alzheimer’s disease, and prodromal dementia with lewy bodies. Dement Geriatr Cogn Disord. 2020;49:583–588. PubMed

Oswal A, Gratwicke J, Akram H, et al. . Cortical connectivity of the nucleus basalis of Meynert in Parkinson’s disease and Lewy body dementias. Brain. 2020;144(3):781–788. PubMed PMC

Ferman TJ, Aoki N, Crook JE, et al. . The limbic and neocortical contribution of alpha-synuclein, tau, and amyloid beta to disease duration in dementia with Lewy bodies. Alzheimers Dement. 2018;14:330–339. PubMed PMC

Kantarci K, Lowe VJ, Boeve BF, et al. . AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81:58–67. PubMed PMC

Gomperts SN, Locascio JJ, Makaretz SJ, et al. . Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 2016;73:1334–1341. PubMed PMC

Graff-Radford J, Boeve BF, Pedraza O, et al. . Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain. 2012;135(Pt 8):2470–2477. PubMed PMC